Neurodegenerative Disease Management is a distinguished journal published by FUTURE MEDICINE LTD, focusing on the pivotal issues surrounding the management of neurodegenerative diseases. Since its inception in 2014, this journal has emerged as a significant resource within the fields of medicine and neurology, currently holding a respected position with a Q2 category ranking in Medicine (miscellaneous) and Q3 in Neurology (clinical) for 2023. With an ISSN of 1758-2024 and E-ISSN 1758-2032, the journal provides a platform for the dissemination of innovative research, clinical practices, and advancements in treatment strategies for conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. The journal is particularly committed to enhancing knowledge sharing among researchers, health professionals, and students, contributing to the collective effort in combatting neurodegenerative diseases. Though not open access, its articles are meticulously curated to ensure high-quality, impactful contributions to the field, making it an essential reference for those engaged in neurology and related disciplines.

The Lancet Neurology is a premier academic journal published by Elsevier Science Inc, specializing in the field of neurology. With a robust impact factor that signifies its authoritative presence, it consistently ranks in the Q1 category for clinical neurology according to the 2023 standards, positioning itself as the leading journal in its domain, ranking #1 out of 400 in Scopus' neurology rankings and placing in the 99th percentile. Since its establishment in 2002, it has provided a vital platform for disseminating innovative research and clinical advances related to neurological disorders. The journal’s precise focus includes cutting-edge studies on neurodegenerative diseases, stroke, epilepsy, and neuroimaging, which are essential for advancing clinical practice and improving patient outcomes. While it does not offer open access, readers can find high-impact research published monthly, making it indispensable for practitioners, researchers, and students eager to stay at the forefront of neurological science.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

ACTA NEUROLOGICA BELGICA is a leading academic journal published by Springer Heidelberg, dedicated to advancing the field of neurology and medicine. With an ISSN of 0300-9009 and E-ISSN 2240-2993, this journal has been a vital resource since its inception, contributing significantly to neurological research and clinical practice. It holds a respectable impact factor with categories spanning from Q2 in Medicine (miscellaneous) to Q3 in Neurology (clinical) as of 2023, indicating its prominence in the scientific community. The journal's extensive coverage since 1959 enhances its historical relevance, while its ongoing publication until 2024 ensures the latest developments are readily accessible. Researchers and practitioners can benefit from its rigorous peer-reviewed articles, which are crucial for staying current in this rapidly evolving discipline. As a scholarly platform, ACTA NEUROLOGICA BELGICA plays a pivotal role in disseminating knowledge and fostering innovation in neurology, making it a must-read for professionals, students, and anyone involved in the field.

Multiple Sclerosis Journal, published by SAGE Publications Ltd, is a leading academic journal in the fields of neurology and clinical neurology, with an impressive impact factor reflecting its critical role in neurological research. Established in 1995 and continuing to 2024, this journal has positioned itself as a premier platform for disseminating innovative and impactful research related to multiple sclerosis, thereby contributing significantly to both clinical practice and scientific advancements in the field. The journal's robust standing is evidenced by its Q1 category rankings, placing it in the top tier of both Neuroscience (Rank #16/192, 91st Percentile) and Clinical Neurology (Rank #35/400, 91st Percentile) categories, making it an essential resource for researchers, healthcare professionals, and students alike. The journal focuses on a wide array of topics, including basic research, clinical trials, and treatment methodologies, ensuring that its readership is well-informed about the latest developments and trends. Access to its articles is through subscription, fostering a reputable environment for quality research dissemination.

Current Journal of Neurology, published by Tehran University of Medical Sciences, is an esteemed Open Access journal dedicated to advancing the field of neurology. Since its inception in 2011, the journal has provided a platform for innovative research and critical discourse in neurology and clinical neurology, with a focus on the latest advancements and methodologies. Although the journal currently holds a Q4 quartile ranking in both neurology and clinical neurology, its goal is to foster the global dissemination of knowledge and ideas relevant to the complexities of neurological disorders. Researchers, professionals, and students exploring this dynamic field will find valuable insights, as the journal aims to bridge the gap between emerging research and clinical application. Based in Tehran, Iran, the Current Journal of Neurology welcomes contributions that enhance understanding and treatment of neurological conditions, thereby promoting evidence-based practices across the globe.

Multiple Sclerosis and Related Disorders, published by Elsevier Science Ltd, is a leading journal that serves as a vital resource in the field of neurology, particularly focused on multiple sclerosis and its associated conditions. This esteemed journal, which holds a Q1 ranking in Medicine (miscellaneous) and Q2 ranking in both Neurology and Clinical Neurology, delivers high-impact research findings and clinical insights crucial for advancing the understanding and management of multiple sclerosis. With an ISSN of 2211-0348 and an E-ISSN of 2211-0356, it provides valuable content from 2012 to 2024 aimed at researchers, healthcare professionals, and students dedicated to improving patient outcomes and fostering innovative strategies in treatment. Additionally, the journal's presence in the Scopus rankings highlights its relevance and influence in the academic community, ranking 121 out of 400 in Clinical Neurology and 59 out of 192 in Neuroscience. This comprehensive platform encourages the dissemination of cutting-edge knowledge and clinical practices, making it an essential tool for those committed to the field of neurology and related research.

REVISTA DE NEUROLOGIA is a distinguished academic journal focusing on the broad fields of neurology and medicine, published in Spain since its inception in 1959. The journal plays a vital role in disseminating significant research findings, clinical studies, and advancements in neurological science, catering to an audience of researchers, clinicians, and students alike. With an ISSN of 0210-0010 and an E-ISSN of 1576-6578, this quarterly publication has maintained its commitment to enhancing the understanding of neurological disorders and therapies through rigorous peer-reviewed articles. While currently not classified as open access, it is indexed in Scopus, holding a rank of #253 out of 400 in the category of Medicine (Neurology), reflecting its relevance in the field with a 36th percentile. The journal is positioned within the Q3 quartile for both Medicine (miscellaneous) and Clinical Neurology categories as of 2023. Based in Barcelona, Spain, it is a vital resource for anyone devoted to the advancement of knowledge and practice in neurology.

npj Parkinsons Disease is a leading open-access journal dedicated to advancing research in the field of Parkinson's disease and related neurodegenerative disorders. Published by NATURE PORTFOLIO, this journal has been on the forefront of scientific inquiry since its inception in 2015, providing a high-quality platform for the dissemination of groundbreaking research. The journal's reputation is underscored by its impressive Q1 rankings in Cellular and Molecular Neuroscience and Neurology categories, as well as its commendable positions in Scopus rankings, placing it within the top echelons of neuroscience and clinical neurology research. With its focus on innovative methodologies and translational studies, npj Parkinsons Disease aims to foster collaboration among researchers, clinicians, and healthcare professionals, ultimately contributing to the improved understanding and treatment of Parkinson's disease. Researchers, professionals, and students are encouraged to explore its rich repository of knowledge, accessible freely since its launch, to stay abreast of the latest developments in this critical area of neuroscience.

NEUROLOGIST, an esteemed journal published by Lippincott Williams & Wilkins, serves as a vital resource in the fields of Neurology and Medicine. With an ISSN of 1074-7931 and an E-ISSN of 2331-2637, this journal has been dedicated to advancing the understanding of neurological disorders since its inception in 1996, with continual contributions through 2024. Achieving a respectable Q3 rank in both Medicine (miscellaneous) and Neurology (clinical), it provides an essential platform for disseminating innovative research and clinical studies. Although it is not an open-access publication, NEUROLOGIST promotes a rich exchange of ideas and findings for researchers, healthcare professionals, and students alike, helping to bridge the gaps in neurological research and practice. The journal is recognized for its commitment to enhancing clinical practice and research methodology, making it a valuable asset for anyone engaged in the dynamic field of neurology.